Latest Insider Transactions at Ptc Therapeutics, Inc. (PTCT)
This section provides a real-time view of insider transactions for Ptc Therapeutics, Inc. (PTCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PTC THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PTC THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
6,762
-2.19%
|
$378,672
$56.96 P/Share
|
|
Mar 14
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,458
-5.32%
|
$245,190
$55.19 P/Share
|
|
Mar 13
2025
|
Stephanie Okey |
SELL
Open market or private sale
|
Direct |
5,000
-36.06%
|
$270,000
$54.0 P/Share
|
|
Mar 12
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
15,521
-6.73%
|
$822,613
$53.27 P/Share
|
|
Mar 12
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,521
+6.14%
|
$512,193
$33.02 P/Share
|
|
Mar 11
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
7,381
-3.4%
|
$391,193
$53.01 P/Share
|
|
Mar 11
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,381
+3.26%
|
$243,573
$33.02 P/Share
|
|
Mar 10
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
68,039
-12.57%
|
$3,538,028
$52.89 P/Share
|
|
Mar 10
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
68,039
+13.74%
|
$2,041,170
$30.58 P/Share
|
|
Mar 04
2025
|
Allan Steven Jacobson |
SELL
Open market or private sale
|
Direct |
1,230
-6.04%
|
$62,730
$51.52 P/Share
|
|
Feb 20
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
34
-0.57%
|
$1,700
$50.12 P/Share
|
|
Feb 20
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,578
-1.55%
|
$78,900
$50.12 P/Share
|
|
Feb 20
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,614
-1.53%
|
$80,700
$50.12 P/Share
|
|
Feb 20
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
962
-1.24%
|
$48,100
$50.12 P/Share
|
|
Feb 20
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-1.39%
|
$194,750
$50.12 P/Share
|
|
Feb 20
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,567
-1.83%
|
$78,350
$50.12 P/Share
|
|
Feb 20
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,167
-1.54%
|
$58,350
$50.12 P/Share
|
|
Feb 20
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
878
-1.38%
|
$43,900
$50.12 P/Share
|
|
Feb 19
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
34
-0.57%
|
$1,700
$50.1 P/Share
|
|
Feb 19
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,300
-1.26%
|
$65,000
$50.1 P/Share
|
|
Feb 19
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,333
-1.25%
|
$66,650
$50.1 P/Share
|
|
Feb 19
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
795
-1.01%
|
$39,750
$50.1 P/Share
|
|
Feb 19
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,897
-1.37%
|
$194,850
$50.1 P/Share
|
|
Feb 19
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,378
-1.59%
|
$68,900
$50.1 P/Share
|
|
Feb 19
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,168
-1.52%
|
$58,400
$50.1 P/Share
|
|
Feb 19
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
879
-1.37%
|
$43,950
$50.1 P/Share
|
|
Jan 08
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
107
-1.76%
|
$4,708
$44.5 P/Share
|
|
Jan 08
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,552
-1.48%
|
$68,288
$44.5 P/Share
|
|
Jan 08
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,998
-1.84%
|
$87,912
$44.5 P/Share
|
|
Jan 08
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,198
-1.5%
|
$52,712
$44.5 P/Share
|
|
Jan 08
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,402
-0.84%
|
$105,688
$44.5 P/Share
|
|
Jan 08
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
2,136
-2.4%
|
$93,984
$44.5 P/Share
|
|
Jan 08
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,662
-2.52%
|
$73,128
$44.5 P/Share
|
|
Jan 07
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
55
-0.9%
|
$2,475
$45.34 P/Share
|
|
Jan 07
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,265
-1.19%
|
$56,925
$45.34 P/Share
|
|
Jan 07
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,543
-1.4%
|
$69,435
$45.34 P/Share
|
|
Jan 07
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
810
-1.0%
|
$36,450
$45.34 P/Share
|
|
Jan 07
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,142
-0.74%
|
$96,390
$45.34 P/Share
|
|
Jan 07
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,599
-1.77%
|
$71,955
$45.34 P/Share
|
|
Jan 07
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,291
-1.92%
|
$58,095
$45.34 P/Share
|
|
Jan 03
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+19.53%
|
-
|
|
Jan 03
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+22.67%
|
-
|
|
Jan 03
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+19.55%
|
-
|
|
Jan 03
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+19.87%
|
-
|
|
Jan 03
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
715
+10.43%
|
-
|
|
Jan 03
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+15.19%
|
-
|
|
Jan 03
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+14.02%
|
-
|
|
Jan 03
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+17.23%
|
-
|
|
Jan 03
2025
|
Michael Schmertzler |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+5.74%
|
-
|
|
Jan 03
2025
|
Allan Steven Jacobson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+16.43%
|
-
|